US Patent Issued to Jiangsu Hengrui Pharmaceuticals on June 16 for "Dual-agonist compound for both GLP-1 and GIP receptors and application thereof" (Chinese Inventors)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,653,865, issued on June 16, was assigned to Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Lianyungang, China).

"Dual-agonist compound for both GLP-1 and GIP receptors and application thereof" was invented by Fangzhou Wu (Beijing), Lei Wang (Beijing), Xuchao Huang (Beijing), Ran Wu (Beijing), Renzhi Liu (Beijing) and Haiqing Hua (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a dual-agonist compound for both Glucagon-like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) receptors and application thereof. In particular, provided are a polypeptide analog derived from GLP-1 and a pharmaceutically acceptable salt there...